Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19.

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) infection is being one of the most significant challenges of health care systems worldwide. Bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 (COVID-19) are uncommon but consumption of antibiotics and antifungals has increased dramatically during the ongoing pandemic resulting in increased selective pressure for global antimicrobial resistance. Nosocomial bacterial superinfections appear to be more frequent than community-acquired coinfections, particularly among patients admitted to the intensive care unit (ICU) and those receiving immunosuppressive treatment. Fungal infections associated with COVID-19 might be missed or misdiagnosed. Existing and new antimicrobial stewardship (AMS) programmes can be utilized directly in COVID-19 pandemic and are urgently needed to contain the high rates of misdiagnosis and antimicrobial prescription. The aim of this review is to describe the role of bacterial and fungal infections and possible strategies of AMS to use in daily practice for optimal management of COVID-19.

• Authors: Maddalena Peghin, Antonio Vena, Elena Graziano, Daniele Roberto Giacobbe, Carlo Tascini, Matteo Bassetti
• Journal: Therapeutic advances in infectious disease (Ther Adv Infect Dis) 2022 Jan-Dec Vol. 9 Pg. 20499361221095732 ISSN: 2049-9361 [Print] England
• PMID: 35591884 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s), 2022.